Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-.beta.
US4737462A · kind A · utility
178Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 10, 1985 |
| Grant date | Apr 12, 1988 |
| Priority date | — |
| Expiry date | Jul 10, 2005 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/142
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A modified IFN-.beta. is provided wherein the cysteine residue at position 17 is deleted and serine is substituted therefor. DNA sequences coding for the modified protein, nucleotide primers used for the mutagenesis, appropriate cloning vectors, host organisms transformed with the vectors, methods for the production and use of the modified IFN-.beta. (IFN-.beta..sub.ser17) are also provided. The specific activity of IFN-.beta..sub.ser17 is found to be substantially the same as that of native IFN-.beta..
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.